➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
AstraZeneca
Dow
McKesson
Johnson and Johnson

Last Updated: October 22, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for CC-11050

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug CC-11050?

CC-11050 is an investigational drug.

There have been 4 clinical trials for CC-11050. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2016.

The most common disease conditions in clinical trials are Tuberculosis, Lupus Erythematosus, Systemic, and Lupus Erythematosus, Discoid. The leading clinical trial sponsors are Celgene, The Leprosy Mission Nepal, and The Aurum Institute NPC.

There are nineteen US patents protecting this investigational drug and four hundred and forty-eight international patents.

Recent Clinical Trials for CC-11050
TitleSponsorPhase
A Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of a New Spray Dried Dispersion (SDD) Formulation of CC-11050 After Single Dose of CC-11050 and to Evaluate the Pharmacokinetics of CC-11050 Under Fasted and Fed ConCelgenePhase 1
CC-11050 Trial in Nepalese Patients With Erythema Nodosum LeprosumThe Leprosy Mission NepalPhase 2
TB Host Directed TherapyThe Aurum Institute NPCPhase 2

See all CC-11050 clinical trials

Clinical Trial Summary for CC-11050

Top disease conditions for CC-11050
Top clinical trial sponsors for CC-11050

See all CC-11050 clinical trials

US Patents for CC-11050

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CC-11050   Start Trial Pharmaceutically active isoindoline derivatives Celgene Corporation (Warren, NJ)   Start Trial
CC-11050   Start Trial Methods for treatment of chronic uveitis using cyclopropyl-n-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)eth- yl]-3-oxoisoindoline-4-yl}carboxamide Celgene Corporation (Summit, NJ)   Start Trial
CC-11050   Start Trial Pharmaceutically active isoindoline derivates Celgene Corporation (Summit, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
AstraZeneca
Dow
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.